Tasly Pharmaceutical Group's subsidiary has obtained the registration certificate for bosentan dispersible tablets.
Tianjin Tasly Pharmaceutical Group Co., Ltd. (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianjin Tasly Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi"), has recently received the approved and issued Drug Registration Certificate for Bosentan Dispersible Tablets from the National Medical Products Administration. The indication of this drug is for pulmonary arterial hypertension (PAH) (WHO Group 1): to improve pulmonary vascular resistance (PVR) in pediatric patients aged 3 years with idiopathic or congenital PAH; and to treat adult patients with WHO functional class II-IV pulmonary arterial hypertension (PAH) (WHO Group 1).
Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary Jiangsu Tasly Pharmaceutical Group Deyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Deyi") has received the approval and issuance of the Drug Registration Certificate for Bosentan dispersible tablets from the National Medical Products Administration. The drug is indicated for pulmonary arterial hypertension (PAH) (WHO Group 1): to improve pulmonary vascular resistance (PVR) in pediatric idiopathic or congenital PAH patients aged 3 years old; and to treat adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) WHO functional class II-IV.
The approval of the Drug Registration Certificate for Jiangsu Deyi's Bosentan dispersible tablets is considered equivalent to passing the generic drug consistency evaluation, enriching the company's product portfolio.
Related Articles
Techtronic Industries (00669) spent 1.1562 million Hong Kong dollars to repurchase 9,500 shares on June 15th.
ZIJING INTL FIN(08340): Executive Director Ma Jian appointed as Chairman of the Board.
On June 15th, Blue Moon Group (06993) spent HK$11.1499 million to repurchase 3.646 million shares.
Techtronic Industries (00669) spent 1.1562 million Hong Kong dollars to repurchase 9,500 shares on June 15th.
ZIJING INTL FIN(08340): Executive Director Ma Jian appointed as Chairman of the Board.
On June 15th, Blue Moon Group (06993) spent HK$11.1499 million to repurchase 3.646 million shares.
RECOMMEND
